Clinical Trial

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-11.
Trial Details
NCT Number NCT06772870
Lead Sponsor Design Therapeutics, Inc.
Conditions Friedreich Ataxia
Enrollment 36 participants
Start Date 2025-02
Primary Completion 2025-09 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-21